{"favorite_id": 3386, "calc_type": "", "dosing": false, "full_title_en": "Risk Score for Asthma Exacerbation (RSE)", "short_title_en": "Risk Score for Asthma Exacerbation", "medium_description_en": "Predicts likelihood of asthma exacerbation within 6 months.", "short_description_en": "Likelihood of asthma exacerbation within 6 months.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Asthma"], "specialty_en": ["Emergency Medicine", "Family Practice", "Internal Medicine", "Pediatrics", "Primary Care", "Allergy and Immunology"], "chief_complaint_en": ["Shortness of Breath", "Wheezing"], "system_en": ["Respiratory"], "search_abbreviation_en": ["Gina", "acq", "corticosteroid", "inhaled steroid", "FEV1"], "slug": "risk-score-asthma-exacerbation-rse", "seo": {"meta_description_en": "The Risk Score for Asthma Exacerbation (RSE) predicts likelihood of asthma exacerbation within 6 months.", "keywords_en": "Gina, acq, corticosteroid, inhaled steroid, FEV1, 6 month asthma exacerbation risk"}, "content": {"how_to_use": {"use_case_en": "<p>Patients with poorly-controlled asthma.</p>", "pearls_pitfalls_en": "<ul> <li>The Risk Score for Asthma Exacerbation (RSE) suggests which patients will experience an asthma exacerbation within 6 months.</li> <li>The RSE should be further studied - while its validation was large, it was not validated outside of its own derivation cohort.</li> <li>It was developed from pharmaceutical trials of patients with poorly controlled asthma, so it may not be applicable to patients with milder asthma severity.</li> </ul>", "why_use_en": "<p>A score to help determine likelihood of exacerbation may assist in guiding therapy and/or monitoring.</p>"}, "next_steps": {"advice_en": "<p>The RSE has been developed from a large cohort and now requires testing through validation studies.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p>Addition of assigned points.</p>", "more_info_en": "<p><strong>Score interpretation:</strong></p> <div class='table-responsive'> <table class='table table-bordered table-hover'> <tbody> <tr> <th>RSE Score</th> <th>Likelihood of exacerbation in 6 months</th> </tr> <tr> <td>0-10</td> <td>5%</td> </tr> <tr> <td>11-20</td> <td>5-7%</td> </tr> <tr> <td>21-30</td> <td>7-10%</td> </tr> <tr> <td>31-40</td> <td>10-12%</td> </tr> <tr> <td>41-50</td> <td>12-15%</td> </tr> <tr> <td>51-60</td> <td>15-18%</td> </tr> <tr> <td>61-70</td> <td>18-24%</td> </tr> <tr> <td>71-80</td> <td>24-30%</td> </tr> <tr> <td>81-90</td> <td>30-37%</td> </tr> <tr> <td>91-100</td> <td>37-45%</td> </tr> </tbody> </table> </div> <p>For more information on the Global Initiative for Asthma treatment steps, click <a href='http://ginasthma.org/wp-content/uploads/2016/01/GINA_Pocket_2015.pdf' target='_blank'>here</a>.</p>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://www.jacionline.org/article/S0091-6749(14)01187-7/fulltext", "text": "Bateman ED. et al. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. Journal of Allergy and Clinical Immunology, Volume 135, Issue 6, 1457-1464.e4"}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Eric Bateman", "creator_info": {"about_en": "<p>Eric Bateman, MD, is a clinician-scientist at the University of Capetown in South Africa. He is the founder of the University of Cape Town Lung Institute and served as its director for 16 years until 2016. He is now a member of several editorial boards for international respiratory journals and has authored more than 300 papers.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-eric-bateman.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bateman+ED%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "BMI \u226530 kg/m\u00b2", "name": "bmi", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 14}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Asthma Control Questionnaire-5 (ACQ-5) Score", "name": "acq", "options": [{"label": "< 1.5", "value": 0}, {"label": "1.5-2.5", "value": 7}, {"label": "\u22652.5", "value": 13}], "conditionality": "", "show_points": true, "optional": false}, {"type": "radio", "label_en": "Postbronchodilator FEV1 (% Predicted normal value)", "name": "fev", "options": [{"label": "\u226590%", "value": 0}, {"label": "80% to 90%", "value": 13}, {"label": "<80%", "value": 20}], "conditionality": "", "show_points": true, "optional": false}, {"type": "radio", "label_en": "Rescue inhaler usage per day", "name": "reliever", "options": [{"label": "<2", "value": 0}, {"label": "2-4", "value": 11}, {"label": "\u22654", "value": 26}], "conditionality": "", "show_points": true, "optional": false}, {"type": "toggle", "label_en": "Global Initiative for Asthma (GINA) treatment step 4 or higher", "name": "gina", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 27}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Medium-high inhaled steroid/long acting beta agonist", "optional": false}], "md5": "1c32e1ae5dd84dc5d358883607cba282", "related_calcs": [{"calcId": 3384, "short_title_en": "Pediatric Respiratory Assessment Measure", "slug": "pediatric-respiratory-assessment-measure-pram-asthma-exacerbation-severity"}, {"calcId": 790, "short_title_en": "Estimated Peak Flow", "slug": "estimated-expected-peak-expiratory-flow-peak-flow"}, {"calcId": 3383, "short_title_en": "Pediatric Asthma Severity Score", "slug": "pediatric-asthma-severity-score-pass-asthma-exacerbation-severity"}]}